Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia

Table 1

Demographic and baseline characteristics (safety population).

	FCM; ()	SMC; ()
Demographic characteristics
Mean (SD) age, years	31.2 (9.36)	31.4 (8.98)
Race, (%)
White	457 (45.9)	477 (46.7)
African American	391 (39.3)	387 (37.9)
Hispanic	122 (12.2)	135 (13.2)
Asian	5 (0.5)	8 (0.8)
Other	21 (2.1)	15 (1.5)
Mean (SD) height, cm	163.4 (6.93)	163.1 (7.07)
Mean (SD) weight, kg	82.0 (21.71)	82.8 (21.64)
Mean (SD) prepregnancy weight, kg	72.4 (19.96)	73.3 (19.85)
Baseline characteristics
Etiology of anemia, (%)
Postpartum	606 (60.8)	623 (61.0)
Heavy menstrual bleeding	390 (39.2)	399 (39.0)
Cardiac risk factor, (%)
Low	709 (71.2)	723 (70.7)
High	287 (28.8)	299 (29.3)
Poor response to oral iron, (%)
Yes	236 (43.1)	252 (44.4)
No	312 (56.9)	316 (55.6)
Mean (SD) hemoglobin, g/dL	9.9 (1.32)	9.8 (1.29)

FCM = ferric carboxymaltose; SD = standard deviation; SMC = standard medical care.
for ferric carboxymaltose and for standard medical care.
for ferric carboxymaltose and for standard medical care.
Prepregnancy weight for postpartum subjects only; for ferric carboxymaltose and for standard medical care.
If a subject had ≤1 cardiac risk factor (specifically, smoking, high blood pressure, high blood cholesterol, diabetes, overweight or obese, physical inactivity, or family history of heart disease), the subject was categorized as low cardiac risk; if the subject had ≥2 risk factors, they were categorized as high cardiac risk.
for ferric carboxymaltose and for standard medical care.
for ferric carboxymaltose and for standard medical care.